Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,548.00
(
1.89%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,571.23
(
0.13%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech jim post# 192111

Thursday, 07/09/2015 10:24:24 AM

Thursday, July 09, 2015 10:24:24 AM

Post# of 257443
SNY/REGN diss AMGN in today’s PR on Praluent results in Japanese patients:

http://finance.yahoo.com/news/regeneron-sanofi-announce-phase-3-020000500.html

Notably, almost all patients reached their LDL-C target levels while remaining on the 75 mg dose, avoiding the need for overtreatment.

The word, overtreatment is a thinly-veiled disparagement of AMGN’s Repatha, which has only one dosing choice (rather than Praluent’s two doses).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today